Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Danaos Corporation (DAC) Price & Performance

BioNTech SE - ADRTrade
Danaos CorporationTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Danaos Corporation — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while Danaos Corporation trades at $135.01 (market cap $2.52B). The key difference: BioNTech SE - ADR is far larger — about 9.3× Danaos Corporation's market cap, and Danaos Corporation pays a 2.6% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXDAC
Market Cap
$23.31B$2.52B
Sector
HealthTechnology
52-Week High
$119.34$143.15
52-Week Low
$83.89$84.05
Enterprise Value
$6.60B$2.50B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.

Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.

Danaos Corporation

Danaos Corporation (DAC) trades at $140.72, down 1.7% on the day, but maintains strong technical momentum with bullish moving averages and support at $139. The company demonstrates exceptional profitability with 51.26% net income margins and trades at attractive valuations including a P/E of 4.68 and P/B of 0.62. Recent earnings beats and a record $4.6 billion contracted revenue backlog highlight operational strength.

DAC presents compelling value with deep discount to book value and consistent earnings outperformance. Key risks include shipping industry cyclicality and capital expenditure requirements. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's strong fundamentals against sector-specific headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Danaos Corporation

Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.

Read more on DAC